Dr. Harding is an Assistant Professor/Member on the Gastrointestinal Oncology and Early Drug Development Services in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He completed his Internal Medicine training at New York Presbyterian Hospital and his fellowship in Medical Oncology and Hematology at Memorial Sloan Kettering Cancer Center. Dr. Harding was recruited to the faculty in 2013 and his clinic focuses on the care of patients with hepatobiliary tumors and other digestive malignancies. His clinical and translation research focuses of developing new drugs for patients with tumors of the liver and biliary tree. Dr. Harding is an Associate Chair of the Memorial Sloan Kettering Institutional Review Board and Privacy Board, as well as a standing member of Protocol Development Committee, Clinical Genomics Annotation Committee, and other executive committees aiming to improve and streamline clinical and translational research. His research and training have been supported by competitive peer-reviewed funding/awards from the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the Howard Hughes Medical Institute, the Society for Memorial Sloan Kettering, Cycle for Survival, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center. He has published over 100 original peer-reviewed manuscripts with collaborators focused on liver, bile duct cancer, and drug development,